Encompass Health Corporation (EHC) Dividend Safety Gauge & 10-Year DRIP Compounder

The Roarable RQD rating is 77 out of 100, graded B+ and labeled "Roarable Buy — Very Good Cash & Smart-Money Inflow" (). The five pillars are:

• Fundamental Cash Engine: 15 / 20. this pillar reflects ROIC of 13.8% and an FCF yield of 2.92%. For a prospective investor, the cash engine is respectable rather than exceptional: returns on invested capital are solid, but the free cash flow yield of 2.92% implies the market is paying a meaningful premium for each dollar of free cash flow generated.
• Whale 13F Flow: 18 / 20. this is the strongest pillar, described as institutional accumulation and options positioning.
• Insider Conviction: 15 / 20. this reflects SEC Form 4 and Congressional PTR cluster flow. The score indicates moderately positive insider and disclosed-trade activity, though the underlying transactions are not itemized in the source data.
• Macro Regime Fit: 13 / 20. beta is 0.9 and sector sensitivity is reflected here. A beta below 1.0 suggests the stock has historically moved less than the broader market, which can cushion drawdowns but also limits participation in strong market rallies.
• Forensic Balance Sheet: 16 / 20. this pillar reflects Altman Z 3.47, Piotroski F 9/9, and Debt/Equity 0.66. These readings point to a financially sound balance sheet, a relevant consideration for a prospective investor weighing downside risk.

Investor implications: the composite score points to a generally favorable profile, with institutional flow and balance sheet strength as the main supports. The tradeoffs are a relatively elevated trailing P/E of 22.9 (per Market Data), a 2.92% FCF yield, and a macro-sensitivity score that is the weakest of the five pillars. Upside drivers in the data are institutional accumulation and recent earnings momentum; valuation compression or a shift in sector sentiment would be the principal risks to that thesis. This analysis is educational and is not personalized financial advice.

Encompass Health Corporation (EHC) is a NYSE-listed issuer in the Health Care sector, operating in the Hospital/Nursing Management industry..0B. — for the remaining business details.

Revenue rose from $4.80B in FY 2023 to $5.94B in FY 2025, and net income rose from $352.0M to $566.2M over the same span. Per Market Data, the operating margin is 11.6% and the net margin is 9.5%, with ROIC of 13.8%. The Altman Z-Score is 3.47 and the Piotroski F-Score is 9/9, with Debt/Equity at 0.66. The reported debt has trended from $1.67B to $1.72B across the three periods, while cash declined from $85.4M to $72.2M between FY 2024 and FY 2025.

• 🐂 Primary Bull Case: Institutional accumulation (18/20 whale flow pillar) and a Piotroski F-Score of 9/9 combine with a reported Q3 adjusted EPS beat of $1.52 versus $1.36 estimated. With Fundamental Cash Engine at 15/20 (ROIC 13.8%, FCF yield 2.92%) and Institutional Whale Flow at 18/20, sustained execution supports upside toward the top of the $92.77 – $137.27 52-week range.
• 🐻 Primary Bear Case: A trailing P/E of 22.9 and a 2.92% FCF yield leave limited valuation cushion, and the macro-regime pillar is the weakest at 13/20. Investors must weigh 22.9x trailing P/E and 15.8x EV/EBITDA against 11.6% operating margins and a 0.90 macro beta if sector demand softens.

Operating in Hospital/Nursing Management (Health Care), EHC carries a macro regime beta of 0.90 and gross margin of —.

• Key Question #1: What is the composition of revenue and operating income by business segment, and how much depends on payer mix or reimbursement policy?
• Key Question #2: What are the reported EPS and free cash flow figures for the FY periods, since the financials list them as N/A?
• Key Question #3: Why did cash decline between FY 2024 and FY 2025, and what is the debt maturity and refinancing profile behind the $1.72B balance?